ACADIA Pharmaceuticals Current Valuation vs. Net Income
| ACAD Stock | USD 23.99 0.34 1.40% |
For ACADIA Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ACADIA Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ACADIA Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ACADIA Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ACADIA Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.128 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.113 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
ACADIA Pharmaceuticals Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ACADIA Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ACADIA Pharmaceuticals value to that of its competitors to determine the firm's financial worth. ACADIA Pharmaceuticals is rated below average in current valuation category among its peers. It is number one stock in net income category among its peers making up about 0.08 of Net Income per Current Valuation. The ratio of Current Valuation to Net Income for ACADIA Pharmaceuticals is roughly 12.96 . At present, ACADIA Pharmaceuticals' Net Income is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value ACADIA Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ACADIA Current Valuation vs. Competition
ACADIA Pharmaceuticals is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 45.58 Billion. ACADIA Pharmaceuticals holds roughly 2.93 Billion in current valuation claiming about 6% of equities under Health Care industry.
ACADIA Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
ACADIA Pharmaceuticals |
| = | 2.93 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
ACADIA Pharmaceuticals |
| = | 226.45 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
ACADIA Net Income Comparison
ACADIA Pharmaceuticals is currently under evaluation in net income category among its peers.
ACADIA Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ACADIA Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ACADIA Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of ACADIA Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of ACADIA Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 335.8 K | 352.6 K | |
| Operating Income | 207.7 M | 218.1 M | |
| Total Other Income Expense Net | 31.4 M | 32.9 M | |
| Net Income | 203.8 M | 214 M | |
| Income Tax Expense | 36.4 M | 38.2 M | |
| Income Before Tax | 232.3 M | 243.9 M | |
| Net Loss | -194.4 M | -204.1 M | |
| Net Income From Continuing Ops | 260.4 M | 273.4 M | |
| Non Operating Income Net Other | -2.1 M | -2 M | |
| Interest Income | 29.3 M | 30.7 M | |
| Net Interest Income | 29.3 M | 30.7 M | |
| Change To Netincome | 71.2 M | 56.3 M | |
| Net Income Per Share | 1.23 | 1.29 | |
| Income Quality | 0.80 | 0.69 | |
| Net Income Per E B T | 0.79 | 0.81 |
ACADIA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ACADIA Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ACADIA Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ACADIA Pharmaceuticals' important profitability drivers and their relationship over time.
ACADIA Pharmaceuticals Earnings Estimation Breakdown
The calculation of ACADIA Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ACADIA Pharmaceuticals is estimated to be 0.1944 with the future projection ranging from a low of 0.09 to a high of 0.2875. Please be aware that this consensus of annual earnings estimates for ACADIA Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.09 Lowest | Expected EPS | 0.29 Highest |
ACADIA Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of ACADIA Pharmaceuticals' value are higher than the current market price of the ACADIA Pharmaceuticals stock. In this case, investors may conclude that ACADIA Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ACADIA Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 20 | 67.27% | 0.0 | 0.1944 | 1.55 |
ACADIA Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of ACADIA Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ACADIA Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of ACADIA Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.ACADIA Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as ACADIA Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ACADIA Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.ACADIA Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | 0.14 | 0.42 | 0.28 | 200 | ||
2025-08-07 | 2025-06-30 | 0.14 | 0.16 | 0.02 | 14 | ||
2025-05-06 | 2025-03-31 | 0.05 | 0.11 | 0.06 | 120 | ||
2025-02-25 | 2024-12-31 | 0.219 | 0.86 | 0.641 | 292 | ||
2024-11-06 | 2024-09-30 | 0.14 | 0.2 | 0.06 | 42 | ||
2024-08-06 | 2024-06-30 | 0.18 | 0.2 | 0.02 | 11 | ||
2024-05-08 | 2024-03-31 | 0.05 | 0.1 | 0.05 | 100 | ||
2024-02-27 | 2023-12-31 | 0.3 | 0.28 | -0.02 | 6 | ||
2023-11-02 | 2023-09-30 | -0.43 | -0.4 | 0.03 | 6 | ||
2023-08-02 | 2023-06-30 | -0.08 | 0.01 | 0.09 | 112 | ||
2023-05-08 | 2023-03-31 | -0.21 | -0.27 | -0.06 | 28 | ||
2023-02-27 | 2022-12-31 | -0.24 | -0.26 | -0.02 | 8 | ||
2022-11-02 | 2022-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2022-08-08 | 2022-06-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2022-05-04 | 2022-03-31 | -0.6 | -0.33 | 0.27 | 45 | ||
2022-02-28 | 2021-12-31 | -0.24 | -0.27 | -0.03 | 12 | ||
2021-11-08 | 2021-09-30 | -0.26 | -0.09 | 0.17 | 65 | ||
2021-08-04 | 2021-06-30 | -0.3 | -0.27 | 0.03 | 10 | ||
2021-05-05 | 2021-03-31 | -0.53 | -0.42 | 0.11 | 20 | ||
2021-02-24 | 2020-12-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2020-11-04 | 2020-09-30 | -0.38 | -0.54 | -0.16 | 42 | ||
2020-08-05 | 2020-06-30 | -0.44 | -0.27 | 0.17 | 38 | ||
2020-05-07 | 2020-03-31 | -0.48 | -0.57 | -0.09 | 18 | ||
2020-02-26 | 2019-12-31 | -0.36 | -0.34 | 0.02 | 5 | ||
2019-10-30 | 2019-09-30 | -0.4 | -0.29 | 0.11 | 27 | ||
2019-07-31 | 2019-06-30 | -0.45 | -0.38 | 0.07 | 15 | ||
2019-05-01 | 2019-03-31 | -0.52 | -0.59 | -0.07 | 13 | ||
2019-02-26 | 2018-12-31 | -0.55 | -0.5 | 0.05 | 9 | ||
2018-11-06 | 2018-09-30 | -0.58 | -0.5 | 0.08 | 13 | ||
2018-08-08 | 2018-06-30 | -0.45 | -0.51 | -0.06 | 13 | ||
2018-05-04 | 2018-03-31 | -0.55 | -0.44 | 0.11 | 20 | ||
2018-02-27 | 2017-12-31 | -0.58 | -0.55 | 0.03 | 5 | ||
2017-11-07 | 2017-09-30 | -0.62 | -0.53 | 0.09 | 14 | ||
2017-08-08 | 2017-06-30 | -0.72 | -0.55 | 0.17 | 23 | ||
2017-05-09 | 2017-03-31 | -0.73 | -0.72 | 0.01 | 1 | ||
2017-02-28 | 2016-12-31 | -0.65 | -0.65 | 0.0 | 0 | ||
2016-11-07 | 2016-09-30 | -0.56 | -0.61 | -0.05 | 8 | ||
2016-08-04 | 2016-06-30 | -0.49 | -0.63 | -0.14 | 28 | ||
2016-05-05 | 2016-03-31 | -0.42 | -0.45 | -0.03 | 7 | ||
2016-02-29 | 2015-12-31 | -0.38 | -0.45 | -0.07 | 18 | ||
2015-11-05 | 2015-09-30 | -0.4 | -0.39 | 0.01 | 2 | ||
2015-08-06 | 2015-06-30 | -0.33 | -0.39 | -0.06 | 18 | ||
2015-05-07 | 2015-03-31 | -0.27 | -0.4 | -0.13 | 48 | ||
2015-02-26 | 2014-12-31 | -0.26 | -0.28 | -0.02 | 7 | ||
2014-11-10 | 2014-09-30 | -0.22 | -0.25 | -0.03 | 13 | ||
2014-08-05 | 2014-06-30 | -0.19 | -0.22 | -0.03 | 15 | ||
2014-05-06 | 2014-03-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2014-02-27 | 2013-12-31 | -0.13 | -0.13 | 0.0 | 0 | ||
2013-11-06 | 2013-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2013-08-06 | 2013-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2013-05-07 | 2013-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2013-03-12 | 2012-12-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2012-11-05 | 2012-09-30 | -0.09 | -0.04 | 0.05 | 55 | ||
2012-08-08 | 2012-06-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2012-05-08 | 2012-03-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2012-03-06 | 2011-12-31 | -0.1 | -0.1 | 0.0 | 0 | ||
2011-11-09 | 2011-09-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2011-08-10 | 2011-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2011-05-10 | 2011-03-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2011-03-10 | 2010-12-31 | 0.69 | 0.74 | 0.05 | 7 | ||
2010-11-09 | 2010-09-30 | -0.17 | -0.11 | 0.06 | 35 | ||
2010-08-09 | 2010-06-30 | -0.16 | -0.11 | 0.05 | 31 | ||
2010-05-10 | 2010-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2010-03-09 | 2009-12-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2009-11-09 | 2009-09-30 | -0.24 | -0.23 | 0.01 | 4 | ||
2009-08-05 | 2009-06-30 | -0.34 | -0.34 | 0.0 | 0 | ||
2009-05-11 | 2009-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2009-03-09 | 2008-12-31 | -0.37 | -0.38 | -0.01 | 2 | ||
2008-11-05 | 2008-09-30 | -0.45 | -0.42 | 0.03 | 6 | ||
2008-08-05 | 2008-06-30 | -0.46 | -0.49 | -0.03 | 6 | ||
2008-05-05 | 2008-03-31 | -0.46 | -0.44 | 0.02 | 4 | ||
2008-03-05 | 2007-12-31 | -0.46 | -0.46 | 0.0 | 0 | ||
2007-11-05 | 2007-09-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2007-08-06 | 2007-06-30 | -0.39 | -0.29 | 0.1 | 25 | ||
2007-05-08 | 2007-03-31 | -0.43 | -0.42 | 0.01 | 2 | ||
2007-03-06 | 2006-12-31 | -0.44 | -0.42 | 0.02 | 4 | ||
2006-11-06 | 2006-09-30 | -0.4 | -0.38 | 0.02 | 5 | ||
2006-08-08 | 2006-06-30 | -0.36 | -0.43 | -0.07 | 19 | ||
2006-05-10 | 2006-03-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2006-03-01 | 2005-12-31 | -0.38 | -0.44 | -0.06 | 15 | ||
2005-11-10 | 2005-09-30 | -0.3 | -0.53 | -0.23 | 76 | ||
2005-08-10 | 2005-06-30 | -0.29 | -0.26 | 0.03 | 10 | ||
2005-05-11 | 2005-03-31 | -0.4 | -0.31 | 0.09 | 22 | ||
2005-03-03 | 2004-12-31 | -0.41 | -0.44 | -0.03 | 7 | ||
2004-11-10 | 2004-09-30 | -0.37 | -0.37 | 0.0 | 0 | ||
2004-08-11 | 2004-06-30 | -0.66 | -0.42 | 0.24 | 36 |
Use ACADIA Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.ACADIA Pharmaceuticals Pair Trading
ACADIA Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ACADIA Pharmaceuticals position
In addition to having ACADIA Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Copper Thematic Idea Now
Copper
Companies involved in production of copper. The Copper theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project ACADIA Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ACADIA Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ACADIA Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.